A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB)

Through close collaborations across scientific disciplines, A*STAR drives new discoveries in neurometabolism and its potential therapeutic applications.

Gene editing holds promise for treating many conditions, but the bacterial origins of RNA-editing enzymes has been found to activate unwanted immune responses in healthy people.

The discovery of an enzyme that prevents the formation of abnormal blood vessels may enable clinical strategies to manage diabetes-associated blindness.

Researchers perform a head-to-head test on different disinfection methods using ultraviolet light to reveal the optimal protocol for deactivating coronaviruses.

Researchers develop a protocol to boost the effectiveness of and reduce the risk of potential side effects for T cell cancer therapies.

Researchers use single-cell sequencing for a new look at how stem cell-derived retinal cells fare after transplants for degenerative eye disorders.

New associations between COVID-19 and immune responses in cancer patients reveal potential inroads to fighting tumours.

Scientists discover genes encoding colours, scents and bioactive compounds in the genome of Papilionanthe Miss Joaquim, Singapore’s National Flower.

As Sir David and Birgit Lane leave Singapore, A*STAR Research commemorates the legacy that the couple continues to build for their students, colleagues and the nation’s wider research ecosystem.

Researchers have discovered a molecular pathway in colorectal cancer cells that leads to uncontrolled division, creating an avenue for more targeted therapies.

Leveraging on its public sector and industry collaborations, A*STAR and the Experimental Drug Development Centre hold the keys to effective drug discovery and development.

By analysing heart cells, a new machine learning algorithm could help predict arrhythmia risk before symptoms appear.